Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602514 | 0.89 | NSD2 (0.43) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL18602956 | 0.87 | NSD2 (0.51) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL15086697 | 0.86 | NSD2 (0.50) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL17635803 | 0.86 | NSD2 (0.46) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL13083064 | 0.83 | NSD2 (0.48) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL13064206 | 0.83 | NSD2 (0.48) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL13397787 | 0.82 | NSD2 (0.47) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL11920801 | 0.82 | NSD2 (0.43) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL113312 | 0.79 | ALOX5 (0.46) | NSD2HPGDALOX15HSD17B10MAPT | |
| SCHEMBL9282979 | 0.79 | NSD2 (0.42) | NSD2HPGDALOX15HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3000805-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012021712-A1 | TETRACYCLINE ANALOGS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011123536-A1 | POLYCYCLIC TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010129057-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | NSD2 3471/4885HPGD 3299/4885ALOX15 4292/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | NSD2 3715/4885HPGD 2557/4885ALOX15 3910/4885 |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | NSD2 4380/4885HPGD 4789/4885ALOX15 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.